Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2006-08-29
2006-08-29
Helms, Larry H. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C530S317000
Reexamination Certificate
active
07098302
ABSTRACT:
The invention provides methods and compositions for diagnosing and treating subjects using EBPs. Specifically disclosed are peptides and peptidomimetics that bind selectively to the extracellular domain of ErbB2. These compositions are useful in the prevention and treatment of disorders characterized by ErbB2 overexpression (e.g., breast cancer).
REFERENCES:
patent: 5620675 (1997-04-01), McBride et al.
patent: 5910583 (1999-06-01), Marks et al.
patent: 5922845 (1999-07-01), Deo et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6074640 (2000-06-01), Curiel et al.
patent: 6123939 (2000-09-01), Shawver et al.
patent: 6165464 (2000-12-01), Hudziak et al.
patent: 6358525 (2002-03-01), Guo et al.
patent: 6417168 (2002-07-01), Greene et al.
patent: 6723694 (2004-04-01), Ben-Sasson
patent: 2003/0171278 (2003-09-01), Dennis
patent: WO 03/061559 (2003-07-01), None
GENBANK Accession No. AAA75493. HER2 receptor (Homo sapiens) Sep. 18, 1995.
Aasland, R., et al. “Expression of oncogenes in thyroid tumours: coexpression of c-erbB2
eu and c-erbB.”Br J Cancer. Apr. 1988;57(4):358-63. Abstract Only.
Allan, SM., et al., “Radioimmunolocalisation in breast cancer using the gene product of c-erbB2 as the target antigen.”Br J Cancer. Apr. 1993;67(4):706-12. Abstract Only.
Arap, W., et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model.”Science, 279:377-380. (1998).
Braun, S., et al., ErbB2 overexpression on occult metastic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients.Cancer Res. Mar. 1, 2001;61(5):1890-5. Abstract Only.
Carraway, et al., Multiple facets of sialomucin complex/MUC4, a membrane mucin and erbb2 ligand, in tumors and tissues (Y2K update).Front Biosci. Jan. 1, 2000;5:D95-D107. Abstract Only.
Cell Signaling Technology, Inc., HER2/ErbB2 Antibody #2242 product data sheet. 3 pages. Updated Sep. 21, 2001 from cellsignal.com.
Garratt, AN, et al., Neuregulin, a factor with many functions in the life of a schwann cell.Bioessays. Nov. 2000;22(11):987-96. Abstract Only.
GENBANK Accession No. M11730 Human tyrosine kinase-type receptor (HER2) mRNA, complete cds. Sep. 18, 1995.
GENBANK Accession No. X03363, Human c-erb-B-2 mRNA. Mar. 30, 1995.
GENENTECH, Inc., Herceptin® (trastu zumab) Full Prescribing information. 15 pages. Revised Sep. 2000.
Harari, D., et al., Molecular mechanisms underlying ErbB2/HER2 action in breast cancer.Oncogene. Dec. 11, 2000;19(53):6102-14. Abstract Only.
Hijazi, et al., Heregulin regulates the actin cytoskeleton and promotes invasive properties in breast cancer cell lines.Int J Oncol. Oct. 2000;17(4):629-41. Abstract Only.
Huang, G., et al., “Overexpression of ErbB2 impairs ligand-dependent downregulation of epidermal growth factor receptors via a post-transcriptional mechanism.”J Cell Biochem. Jul. 1, 1999;74(1):23-30. Abstract Only.
Jardines, L. et al., neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer.Pathobiology. 1993;61(5-6):268-82. Abstract Only.
Johannessen, Le, et al., Heterodimerization of the epidermal-growth-factor (EGF) receptor and ErbB2 and the affinity of EGF binding are regulated by different mechanisms.Biochem J. May 15, 2001;356(Pt I):87-96. Abstract Only.
Komatsu, M., et al., Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor.Oncogene. Jan. 25, 2001;20(4):461-70. Abstract Only.
Krag, D., et al., “Identification of small peptide ligands to ErbB2.” Department of Defense Era of Hope Meeting, Sep. 25-28, 2002. Orlando, FL. Poster Session Abstract P52-8.
Krag, D., et al., “Phage-displayed random peptide libraries in mice. Toxicity after serial panning.” Department of Defense Era of Hope Meeting, Sep. 25-28, 2002. Orlando, FL. Poster Session Abstract P52-9.
Kumar, R., et al., New insights into anti-HER-2 receptor monoclonal antibody research.Semin Oncol. Dec. 2000;27(6 Suppl 11):84-91; discussion 92-100. Abstract Only.
Lupu, R., et al., William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer.Breast Cancer Res Treat. 1993;27(1-2):83-93. Abstract Only.
Menard, S., et al., Role of HER2 gene overexpression in breast carcinoma.J Cell Physiol. Feb. 2000;182(2):150-62. Abstract Only.
Nagy, P., et al., Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.Pathol Oncol Res. 1999;5(4):255-71. Abstract Only.
Natali, PG et al., “Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues.”Int J Cancer. Mar. 15, 1990;45(3):457-61. Abstract Only.
Oligino, L., et al., (1997) “Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain.”J. Biol. Chem. 272(46):29046-29052.
Ouyang, X., et al., Association of ErbB2 Ser1113 phosphorylation with epidermal growth factor receptor co-expression and poor prognosis in human breast cancer.Mol Cell Biochem. Feb. 2001;218(1-2):47-54. Abstract Only.
Park, B-W., et al., (2000) “Rationally designed anti-HER2
eu peptide mimetic disables P185HER2
eu tyrosine kinases in vitro and in vivo.”Nat Biotechnol. 18(2):194-8.
Pegram, M., et al., Biological rationale for HER2
eu (c-erbB2) as a target for monoclonal antibody therapy.Semin Oncol. Oct. 2000;27(5 Suppl 9):13-9. Abstract Only.
Porcelli, B., et al., Expression of p185 and p53 in benign and malignant colorectal lesions.Histochem J. Jan. 2001;33(1):51-7. Abstract Only.
Riviere, A., et al., “Expression of c-erbB2 and c-myc in squamous epithelia and squamous cell carcinomas of the head and neck and the lower female genital tract.”J Oral Pathol MedOct. 1990;19(9):408-13. Abstract Only.
Schier R, et al., “In vitro and in vivo characterization of a human anti-c-erbB-2 single-chain Fv isolated from a filamentous phage antibody library.”ImmunotechnologyMay 1995;1(1):73-81. Abstract and selected pages from article (pp. 77, 80-81).
Schier R, et al., “Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.”J Mol BiolNov. 8, 1996;263(4):551-67. Abstract and article.
Weinstein, EJ, et al. The extracellular region of heregulin is sufficient to promote mammary gland proliferation and tumorigenesis but not apoptosis.Cancer Res. Jul. 15, 2000;60(14):3856-61. Abstract Only.
Zajchowski D, et al., “Expression of growth factors and oncogenes in normal and tumor-derived human mammary epithelial cells.”Cancer ResDec. 15, 1988;48(24 Pt I):7041-7. Abstract Only.
Krag David N.
Oligino Lyn
Pero Stephanie C.
Helms Larry H.
Sang Hong
University of Vermont and State Agricultural College
Wolf Greenfield & Sacks P.C.
LandOfFree
Binding peptides specific for the extracellular domain of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Binding peptides specific for the extracellular domain of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Binding peptides specific for the extracellular domain of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3640872